Drug Profile
Research programme: FLT3 inhibitors - Vichem Chemie
Latest Information Update: 07 Jun 2022
Price :
$50
*
At a glance
- Originator Vichem Chemie
- Class
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 07 Jun 2022 Preclinical development is ongoing in Hungary (Vichem Chemie pipeline, June 2022)
- 07 Jun 2022 Research programme: FLT3 inhibitors - Vichem Chemie is available for licensing as of 07 Jun 2022. https://vichemchemie.com/
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Hungary